Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings released March 10, 2026; full results in Exhibit 99.1.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released March 10, 2026; full results in Exhibit 99.1
- ADCT is a clinical-stage antibody-drug conjugate company: revenue and cash runway figures in the press release are key investor metrics to review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.